Cancer Progress

Since 1985, Cancer Progress is the only oncology conference that invites a discussion of scientific progress within the context of development, regulatory, clinical, commercial and investment perspectives in two days of interactive dialogue. Pivotal topics, frank discussions, vigorous debate, lively audience participation and generous networking throughout the meeting during breaks, luncheons, reception and dinner combine to make this a highly impactful conference.

Our 28th Annual Meeting on March 7-8, 2017 will provide an unsurpassed learning experience for participants in quality of information, coverage of issues, and value of professional contacts. The quality of the speaking faculty is a major contributor to the popularity and value of this conference.

We look forward to seeing you at the 28th Annual Cancer Progress Conference on March 7-8, 2017 at the Westin New York at Times Square!

Registration

Cancer Progress 2017 Registration Rate

Early Bird Special (Pharma, Biotech, Device, Dx): $1900

Regular Rate as of November 1 (Pharma, Biotech, Device, Dx): $2150

Industry Additional registrant from the same company: $1900
Industry one day rate: $1350
Service Provider: $2500
Service Provider one day rate: $1500

The registration fee covers your attendance at the meeting, handbook, continental breakfasts,
luncheons and reception.

Registration Cancellation Policy:

Registrants may cancel up to February 1 for a full refund less a $200 processing charge.

Cancellations after 30 days prior to the conference: Please send someone in your stead, or we will apply a
credit to Cancer Progress 2018 on your behalf.

Please submit conference refund requests to Ginny Llobell at gllobell@definedhealth.com
or call 973.292.5001 Extensions 252 or 235 for assistance.

Venue

The Westin New York at Times Square
270 West 43rd Street | New York, NY 10036
Phone: 212-201-2700 | Fax: 212-201-2799
http://www.westinny.com/

 

times-square 

Advisory Board

Steven Averbuch

Steven D. Averbuch, MD

Vice President,Translational Clinical Development & Pharmacodiagnostics, Bristol-Myers Squibb
JBockman

Jeffrey M. Bockman, PhD

Vice President, Defined Health
RobertCohen

Robert Cohen, MD

Fellow, Calico Life Sciences
RGaynor

Richard B. Gaynor, MD

Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit, Eli Lilly and Company
JGoldberg

Jeremy Goldberg

President, JPG Healthcare LLC
SHeller

Steve Heller

Principal, OncStrat LLC
BLeyland

Brian Leyland-Jones, MD, PhD

Vice President of Molecular and Experimental Medicine, Avera Cancer Institute, Consulting Professor, Stanford University School of Medicine
NRosen

Neal Rosen, MD, PhD

Director, Center for Mechanism-Based Therapeutics, Memorial Sloan Kettering Cancer Center

Testimonials

“I truly enjoyed the conference. I told several colleagues and friends that this has been one of the best conferences I have ever attended.”

Christoph Lengauer, Chief Scientific Officer

Blueprint Medicines

“What an unbelievable 2-day event that was. The intimate atmosphere (I made great new contacts) and dynamic (sometimes “dynamic tension”) interaction between panel members was fantastic. I kept great notes and have already shared the very enthusiastic feedback & takeaways with my management team.”

Armand Girard, Vice President, Corporate Development

Glycomimetics

“Thank you for the opportunity. I felt privileged to be part of a panel composed of stellar leaders within the Oncology space.”

Noemi Rosa

Novartis Inc.

“I really enjoyed the meeting as usual – great topics and speakers. I look forward to next year’s meeting!”

Richard Brian Gaynor, Sr. Vice President Global Development / Medical Affairs, Oncology Business Unit

Eli Lilly and Company